Casdin Capital’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.81M Buy
+75,000
New +$3.5M 0.29% 30
2025
Q2
Sell
-225,000
Closed -$6.38M 38
2025
Q1
$6.38M Buy
225,000
+50,000
+29% +$1.77M 0.52% 27
2024
Q4
$7.28M Buy
+175,000
New +$8.36M 0.48% 25
2023
Q1
Sell
-60,000
Closed -$10.8M 46
2022
Q4
$10.8M Buy
60,000
+27,500
+85% +$4.5M 0.84% 29
2022
Q3
$3.84M Buy
+32,500
New +$4.93M 0.25% 30

Other funds holding MRNA

Casdin Capital's MRNA Position: Q1 2026 in Review

Casdin Capital opened a new position in Moderna (MRNA) in Q1 2026: 75,000 shares worth $3.81M. The stake represents 0.29% of the portfolio and ranks #30 among its holdings. This is a return to the name: Casdin Capital previously reported a position in MRNA as recently as Q1 2025.

Casdin Capital first reported a position in MRNA in Q3 2022 and has held it in 5 quarters since. The position peaked at $10.8M in Q4 2022. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Casdin Capital held 75,000 shares of Moderna worth $3.81M as of Q1 2026.
  • Moderna was a new Casdin Capital position in Q1 2026.
  • Moderna made up 0.29% of Casdin Capital's portfolio in Q1 2026, its #30 holding.
  • Casdin Capital first reported a position in Moderna in Q3 2022 and has held it in 5 quarters since.
  • Casdin Capital's Moderna position peaked at $10.8M in Q4 2022.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.